16-07-2025
TD Cowen Keeps Their Buy Rating on Standard BioTools (LAB)
TD Cowen analyst Kyle Boucher maintained a Buy rating on Standard BioTools today and set a price target of $2.50. The company's shares closed today at $1.22.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Standard BioTools with a $2.50 average price target.
The company has a one-year high of $2.41 and a one-year low of $0.92. Currently, Standard BioTools has an average volume of 1.79M.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LAB in relation to earlier this year. Most recently, in May 2025, Alex Kim Hanjoon, the CFO of LAB sold 1,428.00 shares for a total of $1,342.32.
